Pennington, NJ – According to filings with the U.S. Securities and Exchange Commission, Gennao Bio is raising $40,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Chris Duke played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Gennao Bio

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and systemically deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells, including mRNA, synthetic RNA, DNA, si-RNA, ASOs and gene-editing molecules. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

To learn more about Gennao Bio, visit http://gennao.com/

Contact:
Chris Duke, Chief Executive Officer
212-739-6400

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved